drugset / Trial / NCT03144245
Study of AMV564 in Patients With AML
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a first in human, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of AMV564.
Timeline
- Start
- 2017-03-20
- Primary completion
- 2020-07-21
- Completion
- 2020-11-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMV564 | Protein / enzyme biologic | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |